MannKind

FDA’s OPDP Warns MannKind for Facebook Post
FDA’s OPDP Warns MannKind for Facebook Post
RAPS.org
Afrezza
warning letter
FDA
OPDP
Facebook
social media
diabetes
MannKind
Flag link:
Struggling MannKind sees shares rocket up on $105M-plus alliance with United on inhaled treprostinil
Struggling MannKind sees shares rocket up on $105M-plus alliance with United on inhaled treprostinil
Endpoints
MannKind
United Therapeutics
PAH
Treprostinil
Flag link:
Can MannKind Corporation Avert Bankruptcy?
Can MannKind Corporation Avert Bankruptcy?
Motley Fool
MannKind
earnings
Afrezza
Flag link:
MannKind (MNKD) Completes Phase 1 Trial of Treprostinil Technosphere for PAH Advancing Development to Next Phase
MannKind (MNKD) Completes Phase 1 Trial of Treprostinil Technosphere for PAH Advancing Development to Next Phase
Street Insider
MannKind
TreT
FDA
PAH
Flag link:
MannKind Q1 Results: The Good, the Bad, and the Ugly
MannKind Q1 Results: The Good, the Bad, and the Ugly
Motley Fool
MannKind
earnings
Flag link:
Why MannKind Corporation Stock Broke Down in April
Why MannKind Corporation Stock Broke Down in April
Motley Fool
MannKind
Flag link:
3 Bright Spots in MannKind Corporation's Q4 Update
3 Bright Spots in MannKind Corporation's Q4 Update
Motley Fool
MannKind
earnings
Flag link:
Why MannKind Corporation Stock Is Falling Back to Earth Today
Why MannKind Corporation Stock Is Falling Back to Earth Today
Motley Fool
MannKind
diabetes
Afrezza
Flag link:
3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street
3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street
Motley Fool
diabetes
Senseonics
Lexicon Pharmaceuticals
MannKind
Flag link:
Why MannKind Corporation Jumped Higher Today
Why MannKind Corporation Jumped Higher Today
Motley Fool
MannKind
diabetes
Afrezza
Flag link:
Why MannKind Corporation Dipped 4.8% in November
Why MannKind Corporation Dipped 4.8% in November
Motley Fool
MannKind
earnings
Flag link:
An Interview With MannKind CEO Michael Castagna
An Interview With MannKind CEO Michael Castagna
Motley Fool
MannKind
Michael Castagna
Flag link:
Is MannKind's Debt a Ticking Time Bomb?
Is MannKind's Debt a Ticking Time Bomb?
Motley Fool
MannKind
debt
Flag link:
3 Drug Stocks That Soared This Week
3 Drug Stocks That Soared This Week
Motley Fool
Endocyte
PSMA-617
MannKind
Afrezza
Mylan Labs
generics
Teva Pharmaceutical
Flag link:
FDA approves new label language for Afrezza
FDA approves new label language for Afrezza
Greenwich Citizen, CT
FDA
labeling
Afrezza
inhaled insulin
MannKind
diabetes
Flag link:
Why MannKind Stock Started October With a Bang
Why MannKind Stock Started October With a Bang
Motley Fool
MannKind
inhaled insulin
Afrezza
diabetes
Flag link:
MannKind - Afrezza Scripts Finish August Flat
MannKind - Afrezza Scripts Finish August Flat
Seeking Alpha
MannKind
Afrezza
diabetes
inhaled insulin
Flag link:
MannKind posts mixed Q2
MannKind posts mixed Q2
Drug Delivery Business News
MannKind
earnings
Flag link:
MannKind combines inhaled insulin with One Drop’s digital diabetes tech
MannKind combines inhaled insulin with One Drop’s digital diabetes tech
Drug Delivery Business News
MannKind
inhaled insulin
One Drop
Afrezza
Flag link:
MannKind: Afrezza Television Ad Debuts; What Investors Need To Know
MannKind: Afrezza Television Ad Debuts; What Investors Need To Know
Seeking Alpha
MannKind
Afrezza
drug ads
diabetes
investors
inhaled insulin
Flag link:

Pages